Axa S.A. Sarepta Therapeutics, Inc. Transaction History

Axa S.A.

$33.1 Billion
Q2 2024

A detailed history of Axa S.A. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Axa S.A. holds 58,927 shares of SRPT stock, worth $7.34 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

58,927

Previous 58,894 0.06%

Holding current value

$7.34 Million

Previous $7.62 Million 22.11%

% of portfolio

0.03%

Previous 0.02%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$113.33 - $163.85 $3,739 - $5,407	33 Added 0.06%	58,927 $9.31 Million
Q1 2024 May 15, 2024	BUY	$93.7 - $141.53 $1,405 - $2,122	15 Added 0.03%	58,894 $7.62 Million
Q4 2023 Jul 16, 2024	SELL	$67.31 - $124.76 $1,009 - $1,871	-15 Reduced 0.03%	58,879 $5.68 Million
Q4 2023 Feb 14, 2024	SELL	$67.31 - $124.76 $95,916 - $177,783	-1,425 Reduced 2.36%	58,879 $5.68 Million
Q3 2023 Nov 14, 2023	SELL	$102.5 - $123.59 $21,935 - $26,448	-214 Reduced 0.35%	60,304 $7.31 Million
Q2 2023 Aug 14, 2023	BUY	$106.4 - $157.19 $88,631 - $130,939	833 Added 1.4%	60,518 $6.93 Million
Q1 2023 May 15, 2023	SELL	$117.53 - $155.99 $4.45 Million - $5.91 Million	-37,889 Reduced 38.83%	59,685 $8.23 Million
Q4 2022 Feb 14, 2023	SELL	$100.86 - $132.13 $53,556 - $70,161	-531 Reduced 0.54%	97,574 $12.6 Million
Q3 2022 Feb 14, 2023	BUY	$75.71 - $119.24 $31,268 - $49,246	413 Added 0.42%	98,105 $10.8 Million
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $31,268 - $49,246	413 Added 0.42%	98,105 $10.8 Million
Q2 2022 Feb 14, 2023	SELL	$62.69 - $88.44 $119,361 - $168,389	-1,904 Reduced 1.91%	97,692 $7.32 Million
Q2 2022 Aug 15, 2022	SELL	$62.69 - $88.44 $119,361 - $168,389	-1,904 Reduced 1.91%	97,692 $7.32 Million
Q1 2022 Feb 14, 2023	BUY	$63.15 - $90.42 $94,156 - $134,816	1,491 Added 1.52%	99,596 $7.78 Million
Q1 2022 May 13, 2022	SELL	$63.15 - $90.42 $63 - $90	-1 Reduced -0.0%	99,596 $7.78 Million
Q4 2021 Feb 14, 2022	BUY	$77.28 - $99.42 $91,963 - $118,309	1,190 Added 1.21%	99,597 $8.97 Million
Q3 2021 Nov 15, 2021	BUY	$65.97 - $92.48 $238,613 - $334,500	3,617 Added 3.82%	98,407 $9.1 Million
Q2 2021 Aug 13, 2021	SELL	$69.38 - $86.75 $499,466 - $624,513	-7,199 Reduced 7.06%	94,790 $7.37 Million
Q1 2021 May 14, 2021	BUY	$72.25 - $168.95 $2.18 Million - $5.09 Million	30,107 Added 41.88%	101,989 $7.6 Million
Q4 2020 Feb 12, 2021	BUY	$125.56 - $178.74 $363,747 - $517,809	2,897 Added 4.2%	71,882 $12.3 Million
Q3 2020 Nov 13, 2020	SELL	$127.12 - $172.34 $763,355 - $1.03 Million	-6,005 Reduced 8.01%	68,985 $9.69 Million
Q2 2020 Aug 14, 2020	BUY	$93.0 - $171.7 $773,667 - $1.43 Million	8,319 Added 12.48%	74,990 $12 Million
Q1 2020 May 15, 2020	BUY	$82.38 - $131.64 $306,041 - $489,042	3,715 Added 5.9%	66,671 $6.52 Million
Q4 2019 Feb 18, 2020	BUY	$76.53 - $135.58 $112,499 - $199,302	1,470 Added 2.39%	62,956 $8.12 Million
Q3 2019 Nov 14, 2019	SELL	$72.81 - $156.91 $7,208 - $15,534	-99 Reduced 0.16%	61,486 $4.63 Million
Q2 2019 Aug 13, 2019	SELL	$112.21 - $151.95 $2.33 Million - $3.16 Million	-20,776 Reduced 25.23%	61,585 $9.36 Million
Q1 2019 May 14, 2019	SELL	$106.67 - $151.68 $490,682 - $697,728	-4,600 Reduced 5.29%	82,361 $9.82 Million
Q4 2018 Feb 13, 2019	SELL	$97.32 - $148.76 $9,732 - $14,876	-100 Reduced 0.11%	86,961 $9.49 Million
Q3 2018 Nov 08, 2018	SELL	$115.31 - $161.51 $5,304 - $7,429	-46 Reduced 0.05%	87,061 $14.1 Million
Q2 2018 Aug 13, 2018	BUY	$71.74 - $153.69 $1.97 Million - $4.23 Million	27,514 Added 46.17%	87,107 $11.5 Million
Q1 2018 May 14, 2018	BUY	$54.02 - $82.27 $3.22 Million - $4.9 Million	59,593 New	59,593 $4.42 Million

Others Institutions Holding SRPT

# of Institutions

561

Shares Held

85.5M

Call Options Held

3.67M

Put Options Held

1.75M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.9B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account